share_log

Universe Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Universe Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

大自然藥業 | 6-K:外國發行人報告
美股SEC公告 ·  2024/09/27 13:11

Moomoo AI 已提取核心訊息

At Universe Pharmaceuticals' 2024 Annual General Meeting held on September 27, shareholders approved all nine proposals with strong support, achieving a 55.04% turnout of eligible votes. Key resolutions included increasing the authorized share capital to US$140.6 million and implementing a share consolidation plan.Shareholders re-elected five directors - Gang Lai, Lin Yang, Jiawen Pang, Ding Zheng, and Yongping Yu - each receiving over 98.9% approval. The authorized share capital will expand to accommodate 6.75 billion ordinary shares and 750 million preferred shares, both with a par value of US$0.01875.The approved share consolidation will combine up to 15 existing shares into one new share, with fractional shares rounded up. The Board has discretion to determine the effective date before the next AGM and may adjust the consolidation ratio to no less than 2:1.
At Universe Pharmaceuticals' 2024 Annual General Meeting held on September 27, shareholders approved all nine proposals with strong support, achieving a 55.04% turnout of eligible votes. Key resolutions included increasing the authorized share capital to US$140.6 million and implementing a share consolidation plan.Shareholders re-elected five directors - Gang Lai, Lin Yang, Jiawen Pang, Ding Zheng, and Yongping Yu - each receiving over 98.9% approval. The authorized share capital will expand to accommodate 6.75 billion ordinary shares and 750 million preferred shares, both with a par value of US$0.01875.The approved share consolidation will combine up to 15 existing shares into one new share, with fractional shares rounded up. The Board has discretion to determine the effective date before the next AGM and may adjust the consolidation ratio to no less than 2:1.
在大自然藥業於2024年9月27日舉行的年度股東大會上,股東以強烈的支持批准了所有九項提案,符合資格的投票率達到了55.04%。主要決議包括將授權股本增加至14060萬美元,並實施股份合併計劃。股東重新選舉了五位董事 - 賴剛、楊林、龐家文、鄭丁和虞永平 - 每位的通過率均超過98.9%。授權股本將擴大,以容納67.5億普通股和75000萬優先股,均具有0.01875美元的面值。批准的股份合併將把最多15股現有股份合併爲一股新股,碎股將被取整。董事會有權判斷生效日期,並可在下一次股東大會之前調整合並比例,不得少於2:1。
在大自然藥業於2024年9月27日舉行的年度股東大會上,股東以強烈的支持批准了所有九項提案,符合資格的投票率達到了55.04%。主要決議包括將授權股本增加至14060萬美元,並實施股份合併計劃。股東重新選舉了五位董事 - 賴剛、楊林、龐家文、鄭丁和虞永平 - 每位的通過率均超過98.9%。授權股本將擴大,以容納67.5億普通股和75000萬優先股,均具有0.01875美元的面值。批准的股份合併將把最多15股現有股份合併爲一股新股,碎股將被取整。董事會有權判斷生效日期,並可在下一次股東大會之前調整合並比例,不得少於2:1。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息